Please use this identifier to cite or link to this item:
|Title:||Effect of prechemotherapy filgrastim on the bone marrow toxicity of topotecan|
|Authors:||Uludağ Üniversitesi/Tıp Fakültesi/Kadın Hastalıkları ve Doğum Anabilim Dalı.|
Uludağ Üniversitesi/Tıp Fakültesi/Hemotoloji Anabilim Dalı.
Obstetrics & gynecology
|Citation:||Ozan, H. vd. (2001). "Effect of prechemotherapy filgrastim on the bone marrow toxicity of topotecan". European Journal of Gynaecological Oncology, 22(6), 463-465.|
|Abstract:||Purpose: To investigate the efficacy and safety of single-dose filgrastim administered 24 hours prior to chemotherapy in the prevention of topotecan-related myeloid suppression. Methods: No medication was given to 21 rats in group I; 1.5 mg/m(2)/day topotecan was administered intraperitoneally for five days every three weeks to 21 rats in group 11; a single dose of 5 mug/kg filgrastim was injected intraperitoneally 24 hours before the intraperitoneal administration of the same dose of topotecan to 21 rats in group M. After completion of six cycles of chemotherapy, the rats were decapitated and blood samples were immediately collected into citrated tubes for complete blood counts. Results: White blood cell and lymphocyte counts in the control and the filgrastim + topotecan groups were similar (p > 0.05) and significantly higher than the counts in the topotecan group (p < 0.05). There was no difference in means of neutrophil, monocyte, eosinophil, basophil and erythrocyte counts among the groups (p > 0.05). Conclusion: Filgrastim administration prior to chemotherapy seems to be beneficial and further investigations are needed.|
|Appears in Collections:||Scopus|
Web of Science
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.